• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Avinger Inc. (Amendment)

    8/14/23 3:22:48 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care
    Get the next $AVGR alert in real time by email
    SC 13G/A 1 d408738dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Avinger, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    053734885

    (CUSIP Number)

    August 4, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 053734885       Page 2 of 15

     

      1.    

      Names of Reporting Persons

     

      Nathan D. Hukill

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☒ (1)        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      2,684,160

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      2,684,160

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,684,160

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      19.9% (2)

    12.  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13G.

    (2)

    This percentage is calculated based on 10,821,380 shares of Common Stock issued and outstanding as of July 21, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, plus 2,684,160 shares of Common Stock issuable upon conversion of shares of Series E Convertible Preferred Stock of the Issuer that are beneficially owned by the Reporting Person.


    CUSIP No. 053734885       Page 3 of 15

     

      1.    

      Names of Reporting Persons

     

      CR Group L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☒ (1)        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      2,684,160

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      2,684,160

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,684,160

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      19.9% (2)

    12.  

      Type of Reporting Person (See Instructions)

     

      IA

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13G.

    (2)

    This percentage is calculated based on 10,821,380 shares of Common Stock issued and outstanding as of July 21, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, plus 2,684,160 shares of Common Stock issuable upon conversion of shares of Series E convertible preferred stock of the Issuer that are beneficially owned by the Reporting Person.


    CUSIP No. 053734885       Page 4 of 15

     

      1.    

      Names of Reporting Persons

     

      CRG Partners III L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☒ (1)        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      432,955.008

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      432,955.008

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      432,955.008

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      3.8% (2)

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13G.

    (2)

    This percentage is calculated based on 10,821,380 shares of Common Stock issued and outstanding as of July 21, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, plus 432,955 shares of Common Stock issuable upon conversion of shares of Series E convertible preferred stock of the Issuer that are beneficially owned by the Reporting Person.


    CUSIP No. 053734885       Page 5 of 15

     

      1.    

      Names of Reporting Persons

     

      CRG Partners III Parallel Fund “A” L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☒ (1)        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      232,179.84

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      232,179.84

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      232,179.84

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      2.1% (2)

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13G.

    (2)

    This percentage is calculated based on 10,821,380 shares of Common Stock issued and outstanding as of July 21, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, plus 232,179 shares of Common Stock issuable upon conversion of shares of Series E convertible preferred stock of the Issuer that are beneficially owned by the Reporting Person.


    CUSIP No. 053734885       Page 6 of 15

     

      1.    

      Names of Reporting Persons

     

      CRG Partners III (Cayman) Unlev AIV I L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☒ (1)        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      74,619.648

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      74,619.648

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      74,619.648

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      0.7% (2)

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13G.

    (2)

    This percentage is calculated based on 10,821,380 shares of Common Stock issued and outstanding as of July 21, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, plus 74,619 shares of Common Stock issuable upon conversion of shares of Series E convertible preferred stock of the Issuer that are beneficially owned by the Reporting Person.


    CUSIP No. 053734885       Page 7 of 15

     

      1.    

      Names of Reporting Persons

     

      CRG Partners III (Cayman) Lev AIV I L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☒ (1)        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      920,130.048

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      920,130.048

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      920,130.048

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      7.8% (2)

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13G.

    (2)

    This percentage is calculated based on 10,821,380 shares of Common Stock issued and outstanding as of July 21, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, plus 920,130 shares of Common Stock issuable upon conversion of shares of Series E convertible preferred stock of the Issuer that are beneficially owned by the Reporting Person.


    CUSIP No. 053734885       Page 8 of 15

     

      1.    

      Names of Reporting Persons

     

      CRG Partners III Parallel Fund “B” (Cayman) L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☒ (1)        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      1,024,275.456

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      1,024,275.456

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,024,275.456

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      8.6% (2)

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13G.

    (2)

    This percentage is calculated based on 10,821,380 shares of Common Stock issued and outstanding as of July 21, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, plus 1,024,275 shares of Common Stock issuable upon conversion of shares of Series E convertible preferred stock of the Issuer that are beneficially owned by the Reporting Person.


    CUSIP No. 053734885       Page 9 of 15

     

    Item 1.
       (a)   

    Name of Issuer

     

    Avinger, Inc.

       (b)   

    Address of Issuer ’s Principal Executive Offices

     

    400 Chesapeake Drive, Redwood City, CA 94063

    Item 2.
       (a)   

    Name of Person Filing

     

    This Schedule 13G is filed jointly by the following persons (each a “Reporting Person” and collectively, the “Reporting Persons”):

     

    Nathan D. Hukill

    CR Group L.P.

    CRG Partners III L.P.

    CRG Partners III Parallel Fund “A” L.P.

    CRG Partners III (Cayman) Unlev AIV I L.P.

    CRG Partners III (Cayman) Lev AIV I L.P.

    CRG Partners III Parallel Fund “B” (Cayman) L.P.

          CR Group L.P. may be deemed to beneficially own the shares by virtue of its position as the investment manager for CRG Partners III L.P., CRG Partners III Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund “B” (Cayman) L.P. Mr. Hukill may be deemed to have beneficial ownership over the securities by virtue of his indirect control of CR Group L.P.
       (b)   

    Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of each of the Reporting Persons is 1000 Main Street, Suite 2500, Houston, TX 77002.

       (c)   

    Citizenship

     

    See Row 4 of the cover page for each Reporting Person.

       (d)   

    Title of Class of Securities

     

    Common Stock, par value $0.001 per share

       (e)   

    CUSIP Number

     

    053734885

    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       Not applicable


    CUSIP No. 053734885       Page 10 of 15

     

    Item 4.    Ownership   
       (a)    Amount beneficially owned:   
         

    Nathan D. Hukill

       2,684,160 (1)   
         

    CR Group L.P.

       2,684,160 (1)   
         

    CRG Partners III L.P.

       432,955.008 (1)   
         

    CRG Partners III Parallel Fund “A” L.P.

       232,179.84 (1)   
         

    CRG Partners III (Cayman) Unlev AIV I L.P.

       74,619.648 (1)   
         

    CRG Partners III (Cayman) Lev AIV I L.P.

       920,130.048 (1)   
         

    CRG Partners III Parallel Fund “B” (Cayman) L.P.

       1,024,275.456 (1)   
       (b)    Percent of class:   
         

    Nathan D. Hukill

       19.9% (2)   
         

    CR Group L.P.

       19.9% (2)   
         

    CRG Partners III L.P.

       3.8% (2)   
         

    CRG Partners III Parallel Fund “A” L.P.

       2.1% (2)   
         

    CRG Partners III (Cayman) Unlev AIV I L.P.

       0.7% (2)   
         

    CRG Partners III (Cayman) Lev AIV I L.P.

       7.8% (2)   
         

    CRG Partners III Parallel Fund “B” (Cayman) L.P.

       8.6% (2)   
       (c)    Number of shares as to which the person has:   
          (i) Sole power to vote or to direct the vote:   
         

    Nathan D. Hukill

       0           
         

    CR Group L.P.

       0           
         

    CRG Partners III L.P.

       0           
         

    CRG Partners III Parallel Fund “A” L.P.

       0           
         

    CRG Partners III (Cayman) Unlev AIV I L.P.

    CRG Partners III (Cayman) Lev AIV I L.P.

      

    0        

    0        

      
         

    CRG Partners III Parallel Fund “B” (Cayman) L.P.

       0           
          (ii) Shared power to vote or to direct the vote:   
         

    Nathan D. Hukill

       2,684,160 (1)   
         

    CR Group L.P.

       2,684,160 (1)   
         

    CRG Partners III L.P.

       432,955.008 (1)   
         

    CRG Partners III Parallel Fund “A” L.P.

       232,179.84 (1)   
         

    CRG Partners III (Cayman) Unlev AIV I L.P.

       74,619.648 (1)   
         

    CRG Partners III (Cayman) Lev AIV I L.P.

       920,130.048 (1)   
         

    CRG Partners III Parallel Fund “B” (Cayman) L.P.

       1,024,275.456 (1)   


    CUSIP No. 053734885       Page 11 of 15

     

          (iii) Sole power to dispose or to direct the disposition of:   
         

    Nathan D. Hukill

       0         
         

    CR Group L.P.

       0         
         

    CRG Partners III L.P.

       0         
         

    CRG Partners III Parallel Fund “A” L.P.

       0         
         

    CRG Partners III (Cayman) Unlev AIV I L.P.

    CRG Partners III (Cayman) Lev AIV I L.P.

      

    0      

    0      

      
         

    CRG Partners III Parallel Fund “B” (Cayman) L.P.

       0         
          (iv) Shared power to dispose or to direct the disposition of:   
         

    Nathan D. Hukill

       2,684,160 (1)   
         

    CR Group L.P.

       2,684,160 (1)   
         

    CRG Partners III L.P.

       432,955.008 (1)   
         

    CRG Partners III Parallel Fund “A” L.P.

       232,179.84 (1)   
         

    CRG Partners III (Cayman) Unlev AIV I L.P.

       74,619.648 (1)   
         

    CRG Partners III (Cayman) Lev AIV I L.P.

       920,130.048 (1)   
         

    CRG Partners III Parallel Fund “B” (Cayman) L.P.

       1,024,275.456 (1)   
       (1)    Consists of shares of Common Stock issuable upon conversion of shares of Series E Convertible Preferred Stock.
       (2)    This percentage is calculated based on 10,821,380 shares of Common Stock issued and outstanding as of July 21, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, plus shares of Common Stock issuable upon conversion of shares of Series E Convertible Preferred Stock of the Issuer that are beneficially owned by the Reporting Person.
    Item 5.    Ownership of Five Percent or Less of a Class      
       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐
    Item 6.    Ownership of More than Five Percent on Behalf of Another Person   
       Not applicable      
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       Not applicable      


    CUSIP No. 053734885       Page 12 of 15

     

    Item 8.    Identification and Classification of Members of the Group
       Not applicable
    Item 9.    Notice of Dissolution of Group
       Not applicable
    Item 10.    Certification
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.


    CUSIP No. 053734885       Page 13 of 15

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: August 14, 2023

     

    Nathan D. Hukill
    /s/ Nathan D. Hukill
    An individual
    CR Group L.P.
    CRG Partners III L.P.
    CRG Partners III Parallel Fund “A” L.P.
    CRG Partners III (Cayman) Unlev AIV I L.P.
    CRG Partners III (Cayman) Lev AIV I L.P.
    CRG Partners III Parallel Fund “B” (Cayman) L.P.

     

    By:  

    /s/ Nathan D. Hukill

      Nathan D. Hukill, authorized signatory


    CUSIP No. 053734885       Page 14 of 15

     

    EXHIBITS

     

    A:    Joint Filing Agreement
    Get the next $AVGR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AVGR

    DatePrice TargetRatingAnalyst
    11/15/2021$2.50 → $2.00Buy
    Aegis Capital
    6/29/2021$2.50Buy
    B. Riley Securities
    More analyst ratings

    $AVGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Vice President, Finance Subainati Nabeel Paul sold $699 worth of shares (1,255 units at $0.56), decreasing direct ownership by 28% to 3,296 units (SEC Form 4)

      4 - Avinger Inc (0001506928) (Issuer)

      1/24/25 9:35:20 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Soinski Jeffrey M sold $2,054 worth of shares (3,690 units at $0.56), decreasing direct ownership by 6% to 55,265 units (SEC Form 4)

      4 - Avinger Inc (0001506928) (Issuer)

      1/24/25 9:34:44 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Chief Technology Officer Patel Himanshu sold $1,233 worth of shares (2,215 units at $0.56), decreasing direct ownership by 5% to 39,062 units (SEC Form 4)

      4 - Avinger Inc (0001506928) (Issuer)

      1/24/25 9:34:02 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Avinger Inc.

      SCHEDULE 13G/A - Avinger Inc (0001506928) (Subject)

      2/14/25 5:07:21 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Changes in Registrant's Certifying Accountant, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Avinger Inc (0001506928) (Filer)

      2/10/25 5:01:26 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Avinger Inc (0001506928) (Filer)

      2/5/25 5:00:31 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avinger Reports Third Quarter 2024 Results

      Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development

      11/7/24 4:05:00 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger to Announce Third Quarter 2024 Results on November 7, 2024

      REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co

      10/29/24 8:00:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger Releases Updated Data From IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention

      REDWOOD CITY, CA / ACCESSWIRE / October 24, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease hosted a physician-focused webinar entitled, "New Approaches to Treating Peripheral Artery Disease (PAD) Below-the-Knee (BTK) and Promising New BTK Data." A recording of the webinar may be accessed at https://pages.avinger.com/webinar-new-approaches-to-treating-btk-pad.The webinar featured key opinion leaders in the field of vascular intervention from different specialties and geographies as follows:Dr. Michael Lichtenberg, an angiologist and the

      10/24/24 8:00:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Avinger Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

      REDWOOD CITY, CA / ACCESSWIRE / August 5, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the appointment of Thomas P. Davis, MD, FACC, as Chief Medical Officer for its peripheral business. As a highly experienced interventional cardiologist and key opinion leader (KOL) in the peripheral vascular space, Dr. Davis has operated at the forefront of medical device innovation and advancing patient care in a career spanning more than three decades. Dr. Davis has pioneered the use of several cutting-edge interventional technolo

      8/5/24 8:00:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

      SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

      9/7/22 8:30:00 AM ET
      $AFIB
      $AVGR
      $HYPR
      $NUVA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Avinger Announces Annual Meeting Results

      REDWOOD CITY, CA / ACCESSWIRE / December 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced results of its annual meeting of stockholders (the "Annual Meeting"), concluded on December 23, 2020. At the Annual Meeting, proposals were presented to elect one director to serve until the 2023 annual meeting, to ratify the appointment of the Company's public accountant for the year ended December 31, 2020, to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock spl

      12/23/20 4:50:00 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Financials

    Live finance-specific insights

    See more
    • Avinger Reports Third Quarter 2024 Results

      Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development

      11/7/24 4:05:00 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger to Announce Third Quarter 2024 Results on November 7, 2024

      REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co

      10/29/24 8:00:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger to Announce Second Quarter 2024 Results on August 8, 2024

      REDWOOD CITY, CA / ACCESSWIRE / July 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the second quarter 2024 after the close of trading on Thursday, August 8, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1-848-280-6550 and use passcode Avinger. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.com.A

      7/29/24 8:45:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital reiterated coverage on Avinger with a new price target

      Aegis Capital reiterated coverage of Avinger with a rating of Buy and set a new price target of $2.00 from $2.50 previously

      11/15/21 12:33:44 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities initiated coverage on Avinger with a new price target

      B. Riley Securities initiated coverage of Avinger with a rating of Buy and set a new price target of $2.50

      6/29/21 6:16:21 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avinger Inc.

      SC 13G - Avinger Inc (0001506928) (Subject)

      11/14/24 3:23:30 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avinger Inc.

      SC 13G/A - Avinger Inc (0001506928) (Subject)

      11/13/24 11:13:40 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Avinger Inc.

      SC 13G - Avinger Inc (0001506928) (Subject)

      6/21/24 4:45:23 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care